ResultsIQ › Latest results › Pramodini Medicare Limited
Pramodini Medicare Limited (PRAMODINI) quarterly results
NSE: PRAMODINI · BSE: 000000 · SME
Pramodini Medicare Limited H1 FY27 results
As filed: Revenue ₹37.1 cr, EBITDA ₹16.3 cr, PAT ₹8.3 cr, EBITDA margin 44.0%.
Not scored. Too small to score: half-year revenue ₹37.1 cr is below the ₹40.0 cr minimum. On a base this small, percentage changes say little.
Figures from the company's filings with NSE and BSE. Not investment advice.
About Pramodini Medicare Limited
Pramodini Medicare Limited is an Indian diagnostic services provider offering radiology, clinical laboratory and nuclear medicine tests through hospital partnerships and standalone centres.
What Pramodini Medicare Limited does
Provides technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine to public hospitals, private hospitals, certain PSUs of the Government of India and medical colleges across tier I, tier II and tier III cities throughout India. Radiology covers MRI, CT scan, X-ray, ultrasound with colour doppler, mammography, DEXA scan and intervention radiology. Clinical laboratory covers haematology, microbiology, immunology, pathology and bio-chemistry; nuclear medicine covers PET-CT, SPECT and nuclear therapy. Provides teleradiology services through its registered office at Vijayawada, which functions on a 24x7 basis throughout the year.
How it makes money
- Revenue comes from diagnostic testing services: radiology, clinical laboratory and nuclear medicine, delivered through hospital-based centres and standalone facilities.
- Services are sold through four models: PPP with government hospitals and government teaching hospitals, private-private partnerships with private hospitals, strategic partnerships with PSUs, and private standalone centres.
- A significant portion of revenue from operations is derived from MOUs with government authorities under Public Private Partnership arrangements, per the company's stated risk factors.
- The company derives a substantial portion of its revenue from the state of Andhra Pradesh, per its stated risk factors.
Customers and markets
- Customers are public hospitals, private hospitals, certain PSUs of the Government of India and medical colleges across tier I, tier II and tier III cities throughout India.
- The company says it serves government hospitals, private hospitals, medical colleges and direct patients.
- The company derives a substantial portion of its revenue from the state of Andhra Pradesh, per its stated risk factors.
Segments
- Radiology
- Clinical Laboratory
- Nuclear Medicine
Key facts
- Incorporated: September 12, 2000 as Pramodini Medicare Private Limited with the Registrar of Companies, Andhra Pradesh (September 12, 2000)
- Name change to public limited: Changed to Pramodini Medicare Limited vide fresh certificate of incorporation dated November 12, 2025 (November 12, 2025)
- Registered office: Vijayawada
- Promoters: Chalasani Kuldeep Kumar, Chalasani Kavitha, Chalasani Durga Aashritha, Sri Ram Medicare Private Limit, Chalasani Lalithakumari
- Revenue: ₹62.29 Cr (FY-26)
- Profit after Tax: ₹17.38 Cr (FY-26)
- Net Worth: ₹53.15 Cr (FY-26)
- Debt: ₹17.85 Cr (FY-26)
What the company says sets it apart
- The company says it introduced Vijayawada's first vascular colour Doppler system in 1990 and installed the region's first CT scan in 1993.
- The company says it has a diversified partnership model and broad modality coverage, enabling it to serve tier I, II and III cities with standardized protocols and centralized reporting.
- The company says its model allows asset-light, scalable operations.
- The company says it has a strategic presence across various states of India, a network with diversified models, technical capability with robust IT infrastructure, a dedicated management team with significant industry experience, a track record of revenue and financial performance, and a diverse customer cum patient base.
The company's own claims, as stated in its filings and website.
AI-written from 5 public sources; every line links its source on the page.